Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD

Blood. 2012 Dec 13;120(25):5089-90. doi: 10.1182/blood-2012-09-453928.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Aged
  • Benzamides
  • Child
  • Child, Preschool
  • Chronic Disease
  • Female
  • Graft vs Host Disease / drug therapy*
  • Graft vs Host Disease / pathology
  • Humans
  • Imatinib Mesylate
  • Male
  • Middle Aged
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*
  • Scleroderma, Localized / drug therapy*
  • Scleroderma, Localized / pathology
  • Scleroderma, Systemic / drug therapy*
  • Scleroderma, Systemic / pathology
  • Skin / drug effects
  • Skin / pathology
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate